Biohaven Pharmaceutical Company Leadership
| BHVN Stock | USD 46.01 0.37 0.80% |
About 87 percent of all Biohaven Pharmaceutical's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Biohaven Pharmaceutical Holding suggests that quite a few insiders are very bullish. Biohaven Pharmaceutical employs about 239 people. The company is managed by 31 executives with a total tenure of roughly 93 years, averaging almost 3.0 years of service per executive, having 7.71 employees per reported executive.
| Vlad Coric Chairman Chairman of the Board, Chief Executive Officer |
| Declan Doogan Chairman Independent Chairman of the Board |
Biohaven Pharmaceutical's Insider Buying Vs Selling
87
Selling | Buying |
Latest Trades
| 2024-10-02 | John W Childs | Acquired 21052 @ 47.5 | View | ||
| 2024-09-24 | Gregory Bailey | Acquired 5000 @ 44.19 | View | ||
| 2024-07-18 | John W Childs | Acquired 28400 @ 35.67 | View | ||
| 2024-05-30 | John W Childs | Acquired 28000 @ 35.58 | View | ||
| 2024-05-13 | John W Childs | Acquired 28500 @ 35.17 | View | ||
| 2024-04-24 | Gregory Bailey | Acquired 25503 @ 39.18 | View | ||
| 2024-04-22 | Vlad Coric | Acquired 121951 @ 41 | View | ||
| 2023-12-29 | Irina Antonijevic | Disposed 11000 @ 41.79 | View |
Monitoring Biohaven Pharmaceutical's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Biohaven |
Biohaven Pharmaceutical's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biohaven Pharmaceutical's future performance. Based on our forecasts, it is anticipated that Biohaven will maintain a workforce of about 240 employees by January 2025.Biohaven Pharmaceutical Management Team Effectiveness
The company has return on total asset (ROA) of (1.1879) % which means that it has lost $1.1879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6545) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.87. In addition to that, Return On Capital Employed is likely to drop to -1. At this time, Biohaven Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 2nd of December 2024, Other Current Assets is likely to grow to about 49.7 M, while Total Assets are likely to drop about 347.2 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to drop to about 53.5 M. In addition to that, Net Loss is likely to drop to about (538.9 M)
Biohaven Pharmaceutical Workforce Comparison
Biohaven Pharmaceutical Holding is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 5,135. Biohaven Pharmaceutical holds roughly 239 in number of employees claiming about 5% of equities under Health Care industry.
Biohaven Pharmaceutical Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biohaven Pharmaceutical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biohaven Pharmaceutical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biohaven Pharmaceutical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-12-01 | 6.0 | 12 | 2 | 1,444,384 | 22,000 |
| 2022-12-01 | 2.2034 | 130 | 59 | 18,737,315 | 1,894,630 |
| 2022-09-01 | 0.25 | 1 | 4 | 38,000 | 0.00 |
| 2022-06-01 | 5.0 | 10 | 2 | 79,221 | 6,450 |
| 2022-03-01 | 1.0256 | 40 | 39 | 431,419 | 103,345 |
| 2021-12-01 | 0.6981 | 37 | 53 | 1,230,120 | 1,328,986 |
| 2021-06-01 | 1.75 | 7 | 4 | 84,980 | 38,750 |
| 2021-03-01 | 1.7333 | 26 | 15 | 473,863 | 50,406 |
| 2020-12-01 | 0.3333 | 10 | 30 | 87,525 | 198,986 |
| 2020-09-01 | 1.0 | 6 | 6 | 93,404 | 184,808 |
| 2020-06-01 | 0.3 | 27 | 90 | 837,435 | 2,069,176 |
| 2020-03-01 | 0.7857 | 11 | 14 | 106,748 | 67,819 |
| 2019-12-01 | 0.9048 | 38 | 42 | 811,338 | 635,071 |
| 2019-09-01 | 0.4286 | 3 | 7 | 26,000 | 180,612 |
| 2019-06-01 | 6.5 | 13 | 2 | 220,000 | 88,825 |
| 2019-03-01 | 0.1944 | 7 | 36 | 265,109 | 646,393 |
| 2018-12-01 | 7.0 | 7 | 1 | 485,000 | 40,000 |
| 2018-09-01 | 1.0 | 1 | 1 | 36,000 | 0.00 |
| 2018-06-01 | 0.1667 | 8 | 48 | 125,500 | 555,581 |
| 2018-03-01 | 0.0769 | 5 | 65 | 97,727 | 858,561 |
| 2017-12-01 | 0.2826 | 13 | 46 | 538,814 | 515,304 |
| 2017-09-01 | 5.0 | 5 | 1 | 101,000 | 0.00 |
| 2017-06-01 | 0.2444 | 11 | 45 | 4,688,295 | 7,645,604 |
Biohaven Pharmaceutical Notable Stakeholders
A Biohaven Pharmaceutical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biohaven Pharmaceutical often face trade-offs trying to please all of them. Biohaven Pharmaceutical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biohaven Pharmaceutical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Vlad Coric | Chairman of the Board, Chief Executive Officer | Profile | |
| Declan Doogan | Independent Chairman of the Board | Profile | |
| Kimberly Gentile | Senior Vice President - Clinical Operations | Profile | |
| Matthew Buten | Chief Financial Officer | Profile | |
| James Engelhart | Chief Financial Officer, Treasurer | Profile | |
| John Childs | Independent Director | Profile | |
| Robert Hugin | Independent Director | Profile | |
| Michael Heffernan | Lead Independent Director | Profile | |
| Julia Gregory | Independent Director | Profile | |
| Deb Young | Director Operations | Profile | |
| Gregory Bailey | Independent Director | Profile | |
| Warren JD | General Officer | Profile | |
| John Tilton | Chief Commercial Officer, Rare and Orphan Diseases | Profile | |
| Rajesh Kumar | Senior Chain | Profile | |
| Warren Volles | G Officer | Profile | |
| Chris Barrett | Common Strategy | Profile | |
| Jennifer Porcelli | Vice Relations | Profile | |
| Kishen Mehta | Director | Profile | |
| Megan Dow | Vice Strategy | Profile | |
| Steven Dworetzky | Senior Development | Profile | |
| Dr DACVP | Chief Officer | Profile | |
| Elyse Stock | Chief Medical Officer | Profile | |
| Thomas Lynch | Chairman of the Board | Profile | |
| Marianne MA | Senior Affairs | Profile | |
| Vladimir MD | Chairman CEO | Profile | |
| George Clark | VP Officer | Profile | |
| Gilbert Litalien | Senior Epidemiology | Profile | |
| Charles Conway | Chief Scientific Officer | Profile | |
| Robert Berman | Lead - Special Projects and Medical Oversight | Profile | |
| Clifford MS | Chief Officer | Profile | |
| William Jones | Chief Commercial Officer, Migraine and Common Diseases | Profile |
About Biohaven Pharmaceutical Management Performance
The success or failure of an entity such as Biohaven Pharmaceutical often depends on how effective the management is. Biohaven Pharmaceutical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biohaven management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biohaven management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (0.95) | (1.00) | |
| Return On Assets | (0.80) | (0.84) | |
| Return On Equity | (0.95) | (0.91) |
Biohaven Pharmaceutical Workforce Analysis
Traditionally, organizations such as Biohaven Pharmaceutical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biohaven Pharmaceutical within its industry.Biohaven Pharmaceutical Manpower Efficiency
Return on Biohaven Pharmaceutical Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 13.2M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 12.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.